Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2008

View Archived Issues

ViroPharma to acquire Lev under merger agreement

Topical PSD-503 safe and effective for the treatment of stress urinary incontinence

ABT-925 demonstrates regionally selective dopamine D3 occupancy in humans

MGN-1703 begins phase I cancer study

Erbitux approved in Japan for metastatic colorectal cancer

Enrollment progresses in phase II RA study of CH-1504

Provenge studied in localized prostate cancer patients prior to surgery

JN-403, a novel alpha7 nAch receptor profiled at Novartis

Sublingual buprenorphine safe and effective in controlling neonatal abstinence syndrome

Triolex studied in new phase II trial for type 2 diabetes

Recent Dainippon Sumitomo patent describes new analgesic agents

Novel antiinflammatory agents claimed in recent patent literature

Preclinical studies at Karo Bio support the use of ERbeta agonists in treating depression

Sym-001 studied in new phase II trial for ITP

Alzheimer's drug candidate MCD-386 begins phase I trial

Prulifloxacin demonstrates utility in infectious diarrhea

Recent patents disclose new compounds for sleep disorders, anxiety disorders and schizophrenia

Suspension of phase II trial of doxorubicin Transdrug

Japanese approval for Biopten in PKU

Enrollment under way in phase III laquinimod study in RRMS

Enrollment completed in phase I study of Alzheimer's vaccine Affitope AD-01

SPA agreement for LibiGel FSD program in naturally menopausal women

Metabolon expands multistudy agreement with Mitsubishi Tanabe Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...